^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    trastuzumab vedotin (MRG002)

    i
    Company:
    Lepu Med
    Drug class:
    Microtubule inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Apply
    A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer (NCT05754853)
    Phase 3
    Shanghai Miracogen Inc.
    Recruiting
    Last update posted :
    04/13/2023
    Initiation :
    04/06/2023
    Primary completion :
    10/01/2025
    Completion :
    01/01/2027
    HER-2
    |
    HER-2 positive
    |
    gemcitabine • paclitaxel • docetaxel • pemetrexed • trastuzumab vedotin (MRG002)
    A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients (NCT05263869)
    Phase 2
    Shanghai Miracogen Inc.
    Recruiting
    Last update posted :
    12/02/2022
    Initiation :
    03/23/2022
    Primary completion :
    12/01/2022
    Completion :
    10/01/2023
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • trastuzumab vedotin (MRG002)
    A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. (NCT05338957)
    Phase 1/2
    Shanghai Miracogen Inc.
    Recruiting
    Last update posted :
    12/01/2022
    Initiation :
    08/05/2022
    Primary completion :
    06/01/2024
    Completion :
    12/01/2024
    HER-2
    |
    HER-2 expression
    |
    Puyouheng (pucotenlimab) • trastuzumab vedotin (MRG002)
    A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer (NCT04492488)
    Phase 1/2
    Shanghai Miracogen Inc.
    Recruiting
    Last update posted :
    05/06/2022
    Initiation :
    05/24/2021
    Primary completion :
    12/01/2022
    Completion :
    08/01/2023
    HER-2
    |
    HER-2 positive
    |
    trastuzumab vedotin (MRG002)
    A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer (MRG002-006) (NCT04839510)
    Phase 2
    Shanghai Miracogen Inc.
    Recruiting
    Last update posted :
    12/14/2021
    Initiation :
    04/20/2021
    Primary completion :
    06/01/2022
    Completion :
    09/01/2022
    HER-2
    |
    HER-2 positive
    |
    trastuzumab vedotin (MRG002)
    A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer (NCT04837508)
    Phase 2
    Shanghai Miracogen Inc.
    Recruiting
    Last update posted :
    12/10/2021
    Initiation :
    06/07/2021
    Primary completion :
    12/01/2022
    Completion :
    08/01/2023
    HER-2
    |
    HER-2 positive
    |
    trastuzumab vedotin (MRG002)
    A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors (NCT04941339)
    Phase 1
    Shanghai Miracogen Inc.
    Recruiting
    Last update posted :
    12/03/2021
    Initiation :
    11/21/2018
    Primary completion :
    10/01/2022
    Completion :
    10/01/2022
    HER-2
    |
    HER-2 positive
    |
    trastuzumab vedotin (MRG002)
    A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). (NCT05141786)
    Phase 2
    Shanghai Miracogen Inc.
    Not yet recruiting
    Last update posted :
    12/02/2021
    Initiation :
    12/01/2021
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    HER-2
    |
    HER-2 mutation
    |
    trastuzumab vedotin (MRG002)